Himanshu Bhardwaj, MD
Critical Care Medicine · Oklahoma City, OKNPI 1669604450
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,467 of the $2,905 with a category attached, or 84.9%. It is spread thinly across 27 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,992 and has fallen 96.0% since, to $80 in 2025.
Across 136 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$437
- Actelion Pharmaceuticals US, Inc.$336
- GSK$262
- Boehringer Ingelheim$206
- Gilead$206
- Sunovion Pharmaceuticals Inc.$198
- plus $1K from 21 others
Across 8 payments — averaging $2536.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$20K
What the payments were for
- Consulting fees$32511%
- Speaking & faculty fees$1003%
- Food & beverage$2,46785%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 9 | $437 |
| Actelion Pharmaceuticals US, Inc. | 12 | $336 |
| GSK | 17 | $262 |
| Boehringer Ingelheim | 10 | $206 |
| Gilead | 9 | $206 |
| Sunovion Pharmaceuticals Inc. | 10 | $198 |
| AbbVie | 8 | $195 |
| United Therapeutics Corporation | 10 | $194 |
| Genentech USA, Inc. | 9 | $159 |
| AstraZeneca | 10 | $154 |
| Merck | 8 | $129 |
| La Jolla Pharmaceutical Company | 4 | $77 |
| Jazz Pharmaceuticals Inc. | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| Insmed, Inc. | 2 | $35 |
| Portola Pharmaceuticals, LLC | 1 | $25 |
| Philips North America LLC | 1 | $21 |
| Novartis | 1 | $20 |
| Chiesi USA, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
| Electromed, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$325
How this compares
$2,905 in reported general payments places this provider in the 85th percentile of 57 critical care medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orenitram ErTreprostinil Diolamine | 60 | $646,209 |
| UptraviSelexipag | 13 | $271,158 |
| Tyvaso DpiTreprostinil | 11 | $257,683 |
| OfevNintedanib Esylate | 22 | $250,883 |
| Ambrisentan | 37 | $176,152 |
| OpsumitMacitentan | 12 | $154,085 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $36,220 |
| Spiriva HandihalerTiotropium Bromide | 21 | $10,991 |
| Tadalafil | 54 | $10,900 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $7,436 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $6,338 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,528 |
| Ventolin HfaAlbuterol Sulfate | 17 | $949 |
| Sildenafil Citrate | 13 | $467 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $336 | $425,24325 claims |
| Boehringer IngelheimOfev | $206 | $250,88322 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $262 | $43,65664 claims |
| AstraZenecaSymbicort | $154 | $4,52811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 57 critical care medicine providers in Oklahoma.
Other critical care medicine in Oklahoma City
- Obaid AshrafOklahoma City$12K
- Michael HarperOklahoma City$6K
- Syed AnwerOklahoma City$4K
- Victoria KyleOklahoma City$4K
- Mark RolfeOklahoma City$3K
- Brent BrownOklahoma City$2K
- Joseph BrewerOklahoma City$2K
- Mircea MihuOklahoma City$2K
- Laura SwantOklahoma City$1K
- Ali AshrafOklahoma City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.